These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X; Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236 [TBL] [Abstract][Full Text] [Related]
7. Molecularly targeted cancer therapy: some lessons from the past decade. Huang M; Shen A; Ding J; Geng M Trends Pharmacol Sci; 2014 Jan; 35(1):41-50. PubMed ID: 24361003 [TBL] [Abstract][Full Text] [Related]
8. The Emergence of Precision Urologic Oncology: A Collaborative Review on Biomarker-driven Therapeutics. Barbieri CE; Chinnaiyan AM; Lerner SP; Swanton C; Rubin MA Eur Urol; 2017 Feb; 71(2):237-246. PubMed ID: 27567210 [TBL] [Abstract][Full Text] [Related]
9. [Possibilities and limitations of stratified medicine based on biomarkers and targeted therapies in oncology]. Ludwig WD Z Evid Fortbild Qual Gesundhwes; 2012; 106(1):11-22. PubMed ID: 22325103 [TBL] [Abstract][Full Text] [Related]
10. Biomarker Tests for Molecularly Targeted Therapies: Laying the Foundation and Fulfilling the Dream. Lyman GH; Moses HL J Clin Oncol; 2016 Jun; 34(17):2061-6. PubMed ID: 27069080 [TBL] [Abstract][Full Text] [Related]
11. An overview of the NCI precision medicine trials-NCI MATCH and MPACT. Do K; O'Sullivan Coyne G; Chen AP Chin Clin Oncol; 2015 Sep; 4(3):31. PubMed ID: 26408298 [TBL] [Abstract][Full Text] [Related]
12. Targeted therapy in cancer. Tsimberidou AM Cancer Chemother Pharmacol; 2015 Dec; 76(6):1113-32. PubMed ID: 26391154 [TBL] [Abstract][Full Text] [Related]
13. The journey toward personalized cancer therapy. Tulbah A; Chaudhri N; Al Dayel F; Akhtar M Adv Anat Pathol; 2014 Jan; 21(1):36-43. PubMed ID: 24316909 [TBL] [Abstract][Full Text] [Related]
14. Nuclear medicine theranostics comes of age. Herrmann K; Kraus BJ; Hadaschik B; Kunikowska J; van Poppel H; N'Dow J; Sartor O; Oyen WJG Lancet Oncol; 2021 Nov; 22(11):1497-1498. PubMed ID: 34735807 [No Abstract] [Full Text] [Related]
15. Implementing precision medicine initiatives in the clinic: a new paradigm in drug development. Hollebecque A; Massard C; Soria JC Curr Opin Oncol; 2014 May; 26(3):340-6. PubMed ID: 24709975 [TBL] [Abstract][Full Text] [Related]
16. A promising cancer diagnosis and treatment strategy: targeted cancer therapy and imaging based on antibody fragment. Zhao X; Ning Q; Mo Z; Tang S Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):3621-3630. PubMed ID: 31468992 [TBL] [Abstract][Full Text] [Related]
17. Optimizing oncology therapeutics through quantitative translational and clinical pharmacology: challenges and opportunities. Venkatakrishnan K; Friberg LE; Ouellet D; Mettetal JT; Stein A; Trocóniz IF; Bruno R; Mehrotra N; Gobburu J; Mould DR Clin Pharmacol Ther; 2015 Jan; 97(1):37-54. PubMed ID: 25670382 [TBL] [Abstract][Full Text] [Related]
18. Targeted therapies of solid cancers: new options, new challenges. Awada A; Aftimos PG Curr Opin Oncol; 2013 May; 25(3):296-304. PubMed ID: 23493191 [TBL] [Abstract][Full Text] [Related]
19. [Nuclear medicine diagnostics, therapy and theranostics in the context of modern oncology]. Schaefer N; Prior J Ther Umsch; 2019 Sep; 76(4):167-172. PubMed ID: 31498036 [TBL] [Abstract][Full Text] [Related]